Bayer sees FY25 sales EUR 46B-EUR 48B on currency-adjusted basis

On July 31, Bayer (BAYRY) said, “Due to a better-than-expected business performance at Pharmaceuticals in the first half of the year, Bayer is raising its full-year guidance for currency-adjusted sales and earnings. On a currency-adjusted basis, Bayer now expects to post Group sales of EUR 46B to EUR 48B, previous forecast: EUR 45B to EUR 47B, and EBITDA before special items of EUR 9.7B to EUR 10.2B, previous forecast: EUR 9.5B to EUR 10B, for full-year 2025. The company is also raising its guidance for currency-adjusted core earnings per share to EUR 4.80 to EUR 5.30, previous forecast: EUR 4.50 to EUR 5.00. The forecast for currency-adjusted free cash flow remains unchanged at EUR 1.5B to EUR 2.5B. The company’s currency-adjusted guidance for net financial debt remains unchanged at EUR 31B to EUR 32B. For the Pharmaceuticals Division, Bayer now expects to post currency- and portfolio-adjusted sales growth of 0 to plus 3 percent, previous forecast: minus 4 to minus 1 percent, and a currency-adjusted EBITDA margin before special items of 24 to 26 percent, previous forecast: 23 to 26 percent. For Crop Science, the company is reaffirming its previous guidance. For the Consumer Health Division, the company now expects currency- and portfolio-adjusted sales growth to come in at the lower end of the projected range of plus 2 to plus 5 percent, while the forecast for the currency-adjusted EBITDA margin before special items remains unchanged at 23 to 24 percent. Bayer is continuously evaluating the impacts of the current geopolitical developments, especially in relation to tariffs from the US government. The currently projected financial effects are accounted for in the updated full-year guidance. Bayer expects currency effects to diminish Group sales by around EUR 2B, EBITDA before special items by approximately EUR 500M, and core earnings per share by about EUR 0.35. Regarding net financial debt, the company expects a positive impact of EUR 1.2B from currency.”